Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros


Año de publicación
Intervalo de año de publicación
1.
Int J Dermatol ; 54(11): 1325-32, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26094723

RESUMEN

BACKGROUND: Type 2 lepra reaction (T2R) is a difficult-to-manage condition in leprosy, and an effective and safe steroid-sparing agent is needed for its management. The World Health Organization proposes clofazimine and recommends pentoxifylline for T2R. Our study was done to compare the effectiveness and safety of clofazimine and pentoxifylline therapy in patients with T2R. METHODS: Twenty patients with T2R were randomized equally. Group A received pentoxifylline 400 mg t.d.s, group B received clofazimine 100 mg t.d.s. for 12 weeks. Both groups received prednisolone 40 mg o.d., tapered over 12 weeks. The effectiveness parameters were days needed for resolution of cutaneous and systemic manifestations, relapses, cutaneous score, systemic score, and average daily prednisolone intake. Safety parameters were spontaneously appearing adverse events and laboratory parameter changes. RESULTS: The cutaneous scores in the clofazimine (P < 0.001) and pentoxifylline groups (P < 0.001) showed a progressive decline in subsequent follow-ups. Individual follow-ups were significantly lower than baseline in both groups (P < 0.05). Systemic scores fared similarly. There were no significant intergroup changes. Average daily prednisolone intake progressively decreased in group B (P < 0.001). Cutaneous and systemic manifestations took a comparable time to resolve. Both drugs were safe. CONCLUSION: Pentoxifylline effectively reduces initial severity; clofazimine provides sustained improvement but acts slowly.


Asunto(s)
Artritis Reactiva/microbiología , Clofazimina/uso terapéutico , Leprostáticos/uso terapéutico , Lepra/tratamiento farmacológico , Pentoxifilina/uso terapéutico , Inhibidores de Fosfodiesterasa/uso terapéutico , Adulto , Clofazimina/efectos adversos , Método Doble Ciego , Femenino , Humanos , Inflamación/microbiología , Leprostáticos/efectos adversos , Lepra/complicaciones , Masculino , Persona de Mediana Edad , Neuralgia/microbiología , Pentoxifilina/efectos adversos , Inhibidores de Fosfodiesterasa/efectos adversos , Resultado del Tratamiento , Adulto Joven
2.
Baillieres Clin Rheumatol ; 9(1): 179-91, 1995 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-7728880

RESUMEN

Arthritis is a common feature of leprosy and contributes to disability. Direct invasion of joints and bones by mycobacteria may lead to a destructive arthritis in lepromatous disease. The infective process may involve few or many joints. Reactional states may occur spontaneously but usually after the initiation of anti-mycobacterial treatment. In both the type 1 reaction of borderline case and the type 2 reaction of the lepromatous disease, intense inflammation may occur at sites of infection. The immunology of the reactions is different but they share clinical features including a polyarthritis which may resemble rheumatoid disease. The joint disease may be chronic or relapsing, affecting the wrists and small joints of the hands in particular. Radiological erosions may occur. Mycobacterium leprae is not found in the synovium in this pattern of arthritis. Further study of this phenomenon might yield useful information above the mechanism of joint inflammation in other rheumatic diseases.


Asunto(s)
Artritis Reactiva/etiología , Lepra/complicaciones , Artritis Reactiva/tratamiento farmacológico , Artritis Reactiva/inmunología , Artritis Reactiva/microbiología , Femenino , Humanos , Lepra/inmunología , Lepra/microbiología , Masculino
3.
s.l; s.n; 1995. 13 p. ilus.
No convencional en Inglés | Sec. Est. Saúde SP, HANSEN, Hanseníase, SESSP-ILSLACERVO, Sec. Est. Saúde SP | ID: biblio-1237012
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA